CION Ameerpet
Types & Staging · Reviewed by CION Oncologists · NABH Accredited
Uterine Clear Cell Carcinoma — What It Means
This is an uncommon type of endometrial cancer and a more serious one, and you deserve that stated plainly rather than wrapped up. Clear cell carcinoma is a Type 2 tumour: it is not driven by oestrogen, it is regarded as high grade whatever it looks like, and it has a greater tendency than the common type to invade deeply, involve lymph nodes and spread beyond the pelvis. Alongside that, two things are also true and matter. Stage still dominates the outlook — early-stage clear cell carcinoma is treatable and treated with intent. And because this diagnosis is difficult to make and easy to confuse with others, specialist pathology review genuinely changes diagnoses here.
- Uncommon and more aggressive — stated plainly rather than softened
- High grade by definition — regardless of architecture
- Stage still dominates the outlook — early disease is treated with intent
- Pathology review is worth having — this diagnosis is genuinely difficult
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
How It Differs From the Common Type
Set out directly, because the differences are what drive the different treatment.
| Feature | How clear cell carcinoma differs |
|---|---|
| Not oestrogen-driven | Unlike endometrioid carcinoma, it is not associated with obesity, anovulation or unopposed oestrogen. It occurs in older women and often in women who are not overweight, which is why the usual risk-factor picture does not apply. |
| High grade by definition | It is not graded 1 to 3 in the way endometrioid tumours are. The type itself denotes high grade, because it behaves aggressively regardless of how the tissue is arranged. See how grade is determined. |
| Greater tendency to spread | Deeper myometrial invasion, more lymphovascular space invasion, more frequent lymph node involvement, and a greater tendency to spread within the abdomen by peritoneal routes rather than only through lymphatics. |
| More comprehensive staging surgery | Because of that spread pattern, staging usually includes peritoneal washings, systematic node assessment and omental assessment — more than is done for low-risk endometrioid disease. See lymph nodes. |
| Systemic treatment more often needed | Chemotherapy is recommended for most women beyond the very earliest stage, frequently with radiotherapy alongside. This is a meaningful difference from early low-grade endometrioid cancer, where many women need nothing after surgery. See chemotherapy. |
| Frequently p53-abnormal | Molecular classification often places these tumours in the p53-abnormal group. Testing still matters, because a minority fall elsewhere and that changes the recommendation. See molecular classification. |
| Whole-body imaging more often justified | Because spread beyond the pelvis is more likely, PET-CT has a stronger case here than in early low-grade disease. See PET-CT. |
Stage still matters more than type. Clear cell carcinoma confined to the uterus and completely removed is a substantially different situation from clear cell carcinoma found with spread beyond the pelvis. When you read about this diagnosis, read about your stage rather than about the type in general. See survival by stage.
Did You Know? Clear cell carcinoma of the uterus is uncommon enough that many pathologists see relatively few, and it sits in a genuinely difficult diagnostic space. It can be confused with serous carcinoma, with high-grade endometrioid carcinoma showing clear cell change, and with several benign patterns that produce clear-looking cells. The distinction is not academic: it affects how comprehensively you are staged and what systemic treatment is recommended. Published series consistently find that specialist review of gynaecological pathology changes a proportion of diagnoses in rare subtypes. If you have been given this diagnosis, asking for the slides to be reviewed by a pathologist who reports gynaecological cases regularly is among the most useful things you can do. Sources: WHO Classification of Tumours — Female Genital Tumours; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
How It Is Treated
More intensive than for the common type, and for identifiable reasons.
- Comprehensive surgical staging. Hysterectomy with removal of tubes and ovaries, peritoneal washings, systematic lymph node assessment and omental assessment. The aim is to identify disease that imaging may not show, since that determines what treatment follows.
- Chemotherapy for most women beyond the earliest stage. Systemic treatment is the backbone here rather than an addition, because of the tendency to spread beyond the uterus. The classes used are established and your oncologist will set out the specific plan.
- Radiotherapy alongside, frequently. Often vault brachytherapy, sometimes pelvic radiation, depending on stage and what surgery found. See pelvic radiation.
- Molecular testing, without exception. Most of these tumours are p53-abnormal, and a minority are not — a mismatch repair deficient clear cell carcinoma has systemic treatment options that a p53-abnormal one does not. See MMR and MSI testing.
- Multidisciplinary planning, without exception. This is precisely the situation where the sequence of surgery, chemotherapy and radiotherapy is a genuine decision rather than a default, and it should be made by a full board. See treatment after surgery.
Want the Slides Reviewed Before Treatment?
Rare subtypes are genuinely difficult to diagnose. A specialist gynaecological pathology review is worth having.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Read About Your Stage, Not the Type
Clear cell confined to the uterus is a different situation from clear cell that has spread.
What to Ask For With This Diagnosis
Five things that matter more here than they would with the common type.
A specialist pathology review
The most useful single request. This diagnosis is genuinely difficult and is confused with serous carcinoma, with high-grade endometrioid carcinoma showing clear cell change, and with benign mimics. Review by a pathologist who reports gynaecological cases regularly changes a proportion of rare-subtype diagnoses, and it changes what treatment you receive.
Complete molecular testing
Most of these tumours are p53-abnormal, and the minority that are not have genuinely different options — a mismatch repair deficient tumour opens systemic treatment avenues that would otherwise not be considered. This is not a formality and should not be omitted.
Treatment at a centre that sees these
Comprehensive staging surgery for a non-endometrioid tumour is a different operation from a straightforward hysterectomy for low-grade disease, and it is done better by teams who do it regularly. Ask how many of these the unit treats. See choosing a centre.
A full tumour board discussion
The sequence and combination of surgery, chemotherapy and radiotherapy here is a real decision with several defensible answers. A recommendation assembled by one specialty tends to reflect that specialty's tools. Ask whether your case was discussed and what the board concluded.
A frank conversation about what is known
Because this subtype is uncommon, the evidence base is thinner than for endometrioid cancer and some decisions rest on extrapolation. A doctor who says so is being accurate rather than uncertain, and it is worth asking directly which parts of your plan are well established and which are judgement.
Want a Second Opinion on a Rare Subtype?
Slides reviewed by gynaecological pathologists and your case taken to our tumour board. The opinion is free.
What Is Also True
This page has been deliberately direct. These things are equally accurate.
- Stage dominates, and early stage is common enough. Clear cell carcinoma still frequently presents with postmenopausal bleeding, which brings women in early. Disease confined to the uterus and completely removed is treated with curative intent.
- Treatment here is active and effective. Comprehensive surgery followed by systemic treatment and radiotherapy is a demanding plan and it is a plan that works for many women. It is not a gesture.
- Molecular testing has expanded the options. Particularly in advanced or recurrent disease, where mismatch repair status determines access to classes of treatment that did not exist a decade ago. See advanced disease treatment.
- The diagnosis may change on review. Not a false hope but a real possibility, given how difficult these tumours are to classify. It is worth pursuing before treatment rather than after.
- Statistics describe groups over past decades. They are averages drawn from women treated years ago, across all stages and all circumstances. They are not a prediction about you, and reading them as one is the commonest way this information causes harm. See coping with a diagnosis.
Why Rare Subtypes Belong in Specialist Hands
The diagnosis is difficult, the staging surgery is different, and the treatment decisions are genuinely finely balanced.
Slides reviewed, not just the summary line
Tumour board for every diagnosis
MMR / MSI testing as standard
Sentinel node mapping where it fits
Costs explained before you commit
Second opinions welcomed, not resented
Take The Next Step
Ask for the Slides to Be Reviewed
Specialist review changes a proportion of rare-subtype diagnoses — and changes the treatment that follows.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Clear Cell Carcinoma — Frequently Asked Questions
What is uterine clear cell carcinoma?
It is an uncommon type of endometrial cancer, named for the appearance of its cells, which have clear-looking cytoplasm under the microscope. It is classified as a Type 2 or non-endometrioid tumour, meaning it is not driven by oestrogen — so it does not carry the usual associations with obesity and anovulation, and it tends to occur in older and often thinner women. It is regarded as high grade by definition, whatever the architecture, because it behaves more aggressively than the common endometrioid type: deeper invasion, more lymph node involvement, and a greater tendency to spread beyond the uterus.
Is the outlook worse than for ordinary endometrial cancer?
On average, yes, and it would be wrong to tell you otherwise. Clear cell carcinoma carries a less favourable prognosis than endometrioid carcinoma of the same stage. But stage remains the dominant factor, and that matters practically: clear cell carcinoma confined to the uterus and completely removed is a substantially different situation from disease found to have spread beyond the pelvis. This type still frequently causes postmenopausal bleeding, which brings women in early. When you read about outcomes, read about your stage rather than about the type in general.
Why is a specialist pathology review recommended for this diagnosis?
Because it is genuinely difficult to diagnose and it is uncommon enough that many pathologists see relatively few. Clear cell carcinoma can be confused with serous carcinoma, with high-grade endometrioid carcinoma showing clear cell change, and with several benign patterns that produce clear-looking cells. The distinction is not academic — it determines how comprehensively you are staged and what systemic treatment is recommended. Published series consistently find that specialist gynaecological pathology review changes a proportion of rare-subtype diagnoses. It is worth requesting before treatment starts rather than afterwards.
Why do I need chemotherapy when my friend with endometrial cancer did not?
Because you have a different disease that happens to share a location. Most early, low-grade endometrioid cancers are confined to the uterus, are cured by surgery, and need no systemic treatment at all. Clear cell carcinoma has a much greater tendency to have spread microscopically beyond the uterus by the time it is found, including within the abdomen by peritoneal routes, which is why comprehensive staging surgery and systemic treatment are recommended for most women beyond the very earliest stage. It is not that your team is being more cautious; the biology is different.
Does molecular testing still matter if this type is usually p53-abnormal?
Yes, and it should not be skipped on the assumption that the answer is known. Most clear cell carcinomas do fall into the p53-abnormal group, but a minority do not — and a mismatch repair deficient clear cell carcinoma has systemic treatment options available to it that a p53-abnormal one does not, particularly if the disease is advanced or recurs. Mismatch repair testing also screens for Lynch syndrome, which has implications for your relatives. Since FIGO 2023 incorporates molecular class into staging, testing is part of full staging rather than an optional addition.
Medical disclaimer: This page provides general information about uterine clear cell carcinoma, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Prognosis and treatment depend on stage, extent of surgery, molecular findings and individual circumstances. Because this subtype is uncommon and diagnostically difficult, specialist gynaecological pathology review and multidisciplinary planning are recommended.